S056 Hidradenitis Suppurativa/Acne Inversa (HS/AI): Current Medical and Surgical Management
DESCRIPTION
An evidence-based approach for the use of medical therapies for HS, including topical agents, antibiotics, non-antibiotic systemics, biologics, small molecule inhibitors, pain management and wound care, will be discussed. This session will review hidradenitis suppurativa (HS) epidemiology and comorbidities, and discuss comorbidity screening. An evidence-based approach for the use of surgical therapies for HS, including office-based procedures, will be reviewed. Strategies to increase treatment access and support people with HS in navigating barriers to care will be discussed.
LEARNING OBJECTIVES
Apply appropriate medical, procedural, pain management and wound care strategies for hidradenitis suppurativa.
Describe hidradenitis suppurativa epidemiology and comorbidities, and initiate comorbidity screening.
Apply effective strategies to increase treatment access and support people with HS in navigating barriers to care.
SCHEDULE
1:00 PM
Introduction
Haley Naik, MD, FAAD
1:05 PM
HS Medical Management with Biologics and Small Molecule Inhibitors
Haley Naik, MD, FAAD
1:25 PM
HS Medical Management with Nonbiologic Therapies
Noah Goldfarb, MD, FAAD
1:45 PM
Overcoming Barriers to HS Therapeutic Access
Leandra Alicia Barnes, MD, FAAD
2:05 PM
Navigating Social Determinants in HS Care
Aileen Chang, MD, FAAD
2:25 PM
Moderated Q&A
Haley Naik, MD, FAAD, Noah Goldfarb, MD, FAAD, Aileen Chang, MD, FAAD, Leandra Alicia Barnes, MD, FAAD
2:35 PM
Comorbidity Screening in HS
Stella Chen, MD, FAAD
2:55 PM
Pain Management Considerations for HS
Lauren Orenstein, MD, FAAD
3:10 PM
Wound Care Considerations for HS
Afsaneh Alavi, MD, FAAD
3:30 PM
Office-Based Surgical Procedures for HS
Daniel Mark Klufas, MD, FAAD
3:50 PM
Moderated Q&A
Lauren Orenstein, MD, FAAD, Daniel Mark Klufas, MD, FAAD, Afsaneh Alavi, MD, FAAD, Stella Chen, MD, FAAD
DIRECTOR
Haley Naik, MD, FAAD
SPEAKERS
Afsaneh Alavi, MD, FAAD
Leandra Alicia Barnes, MD, FAAD
Aileen Chang, MD, FAAD
Stella Chen, MD, FAAD
Noah Goldfarb, MD, FAAD
Daniel Mark Klufas, MD, FAAD
Lauren Orenstein, MD, FAAD
DISCLOSURES
Afsaneh Alavi, MD, FAAD
AbbVie – Advisory Board(Honoraria); Almirall – Consultant (1099 relationship)(Honoraria), Data Safety Monitoring Board(Fees); Alumis – Advisory Board(Honoraria); Avalo – Consultant (1099 relationship)(Fees); Boehringer Ingelheim – Investigator(Fees); Cantargia – Consultant (1099 relationship)(Fees); Dermatology Times (MMM MultiMedia Medical, LLC) – Speaker(Honoraria); Incyte Corporation – Consultant(Honoraria); InflaRx – Data Safety Monitoring Board(Honoraria); Leo Foundation – Advisory Board(Honoraria); Novartis – Advisory Board(Honoraria); Sanofi – Advisory Board(Honoraria); Takeda Pharmaceuticals USA Inc – Advisory Board(Honoraria); UCB – Advisory Board(Honoraria); Zura Bio – Data Safety Monitoring Board(Honoraria);
Leandra Alicia Barnes, MD, FAAD
No financial relationships exist with ineligible companies.
Aileen Chang, MD, FAAD
Abridge AI Inc. – Employee (w-2 relationship)(Stock Options);
Stella Chen, MD, FAAD
No financial relationships exist with ineligible companies.
Noah Goldfarb, MD, FAAD
MoonLake Immunotherapeutics – Consultant (1099 relationship)(Fees); Novartis – Investigator(Grants/Research Funding); Sonoma Biotherapeutics – Consultant (1099 relationship)(Fees); UCB – Advisory Board(Fees);
Daniel Mark Klufas, MD, FAAD
No financial relationships exist with ineligible companies.
Haley Naik, MD, FAAD
23andMe – Consultant(Honoraria); AbbVie – Consultant(Honoraria), Other(Grants/Research Funding); Aristea Therapeutics, Inc. – Consultant(Honoraria); Boehringer Ingelheim – Advisory Board(Honoraria); Dava Oncology – Consultant(Honoraria); Johnson and Johnson – Consultant(Honoraria); Medscape – Consultant (1099 relationship)(Fees); Nimbus Therapeutics – Consultant(Honoraria); Novartis – Consultant (1099 relationship)(Fees); Radera Biotherapeutics, Inc. – Stockholder Private Company(Stock Options); Radera, Inc. – Stockholder Private Company(Stock Options); Sonoma Biotherapeutics – Consultant (1099 relationship)(Fees); UCB – Consultant (1099 relationship)(Fees);
Lauren Orenstein, MD, FAAD
HS Foundation – Board of Directors(No Compensation Received); Incyte Corporation – Advisory Board(Fees); Novartis – Advisory Board(Fees), Investigator(Grants/Research Funding); Pfizer Inc. – Investigator(Grants/Research Funding); Phrase Health – Stockholder(Stock); UCB Pharma – Advisory Board(Fees);